Houston is the ninth worst U.S. metro for ozone pollution, but the future isn't foggy. Electric vehicles can improve air quality by 50 percent. Getty Images

Let's clear the air about Houston's air pollution: A recent report from the American Lung Association ranks Houston the ninth worst U.S. metro area for ozone pollution and the 17th worst in the broad category of long-term particle pollution.

Yet the future might not be so cloudy for Houston's atmosphere.

A newly published study in the journal Atmospheric Environment indicates that replacing at least 35 percent of Houston's gas- and diesel-powered cars and trucks with electric vehicles by 2040 could improve air quality by 50 percent. And if electric vehicles replaced 75 percent of traditional cars and trucks by 2040, air quality could improve by 75 percent, according to the study.

This conversion to electric vehicles would enable residents of the Houston area to "breathe easier, live longer, and enjoy a better economy," the researchers say.

"The population in 2040 Houston will see a huge increase, but we can apply new technology to reduce emissions, improve air quality, and think about health," says one of the researchers, Shuai Pan, a postdoctoral associate in civil and environmental engineering at Cornell University.

Pan earned a doctoral degree in atmospheric science from the University of Houston in 2017.

Kevin Douglass, president of the Houston Electric Auto Association, tells InnovationMap that the study does a good job of emphasizing "the alarming situation that Houston is in with reference to its air quality and how electrification of the transportation system is a … way to improve the bad-air-quality situation."

The nonprofit Houston Electric Auto Association comprises EV owners, hobbyists, educators, and enthusiasts who promote the benefits of these vehicles.

Douglass says he's confident about the progression of the EV evolution in Houston.

"It only took a decade to go from horse-drawn carriage to automobile in the U.S.," he says. "One and a half decades from now, in 2035, at least half of the cars on the road will be electric. Thirty years from now, the vast majority of vehicles will be electric and autonomous."

Houston — which the nonprofit Smart Energy Consumer Collaborative praises as one of the 10 friendliest U.S. cities for EVs — already is on the road toward enhancing air quality by putting more electric vehicles (EVs) on the road. In fact, a 2018 report from the Environment Texas Research and Policy Center predicts the number of EVs in Houston will rise to 65,000 by 2030.

An estimated 9,500 EVs were being driven by Houston motorists in 2018, according to a presentation given in May by Michael Conklin, external engagement manager at Houston-based utility CenterPoint Energy. And by 2028, that number could reach 110,000, the presentation says.

"Electric cars aren't the future — they're already here, and they work," Douglass said in 2018. "As more people learn about them, they will enjoy owning and driving them."

Among Houston's highest-profile EV champions is Mayor Sylvester Turner, who's leading the charge to shift the city-owned fleet away from traditional vehicles and toward hybrids and EVs.

"Transportation is responsible for 48 percent of Houston's greenhouse gas emissions — the highest per capita of all U.S. cities — and something we must address to move our city forward," Turner, co-chair of the Climate Mayors organization, said in 2018.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers: Here's what it takes to spot a great new idea

houston voices

Having a “promotion focus” really does create a mental lens through which new ideas are more visible.

Key findings:

  • New ideas can be crucially important to businesses, driving innovation and preventing stagnation.
  • Recognizing those ideas, though, isn’t always easy.
  • Nurturing what is known as “promotion focus” can help managers spot fresh ideas.

Whenever the late surgeon Michael DeBakey opened a human chest, he drew on a lifetime of resources: the conviction that heart surgery could and should be vastly improved, the skill to venture beyond medicine’s known horizons and the vision to recognize new ideas in everyone around him, no matter how little formal training they had.

Appreciating new ideas is the heartbeat of business as well as medicine. But innovation is surprisingly hard to recognize. In a pioneering 2017 article, Rice Business Professor Jing Zhou and her colleagues published their findings on the first-ever study of the traits and environments that allow leaders to recognize new ideas.

Recent decades have produced a surge of research looking at how and when employees generate fresh ideas. But almost nothing has been written on another crucial part of workplace creativity: a leader’s ability to appreciate new thinking when she sees it.

Novelty, after all, is what drives company differentiation and competitiveness. Work that springs from new concepts sparks more investigation than work based on worn, already established thought. Companies invest millions to recruit and pay star creatives.

Yet not every leader can spot a fresh idea, and not every workplace brings out that kind of discernment. In four separate studies, Zhou and her coauthors examined exactly what it takes to see a glittering new idea wherever it appears. Their work sets the stage for an entirely new field of future research.

First, though, the team had to define their key terms. “Novelty recognition” is the ability to spot a new idea when someone else presents it. “Promotion focus,” previous research has shown, is a comfort level with new experiences that evokes feelings of adventure and excitement. “Prevention focus” is the opposite trait: the tendency to associate new ideas with danger, and respond to them with caution.

But does having “promotion focus” as opposed to “prevention focus” color the ability to see novelty? To find out, Zhou’s team came up with an ingenious test, artificially inducing these two perspectives through a series of exercises. First, they told 92 undergraduate participants that they would be asked to perform a set of unrelated tasks. Then the subjects guided a fictional mouse through two pencil and paper maze exercises.

While one exercise showed a piece of cheese awaiting the mouse at the end of the maze (the promise of a reward), the other maze depicted a menacing owl nearby (motivation to flee).

Once the participants had traced their way through the mazes with pencils, they were asked to rate the novelty of 33 pictures — nine drawings of space aliens and 24 unrelated images. The students who were prepped to feel an adventurous promotion focus by seeking a reward were much better at spotting the new or different details among these images than the students who’d been cued to have a prevention focus by fleeing a threat.

The conclusion: a promotion focus really does create a mental lens through which new ideas are more visible.

Zhou’s team followed this study with three additional studies, including one that surveyed 44 human resource managers from a variety of companies. For this study, independent coders rated the mission statements of each firm, assessing their cultures as “innovative” or “not innovative.” The HR managers then evaluated a set of written practices — three that had been in use for years, and three new ones that relied on recent technology. The managers from the innovative companies were much better at rating the new HR practices for novelty and creativity. To recognize novelty, in other words, both interior and external environments make a difference.

The implications of the research are groundbreaking. The first ever done on this subject, it opens up a completely new research field with profound questions. Can promotion focus be created? How much of this trait is genetic, and how much based on natural temperament, culture, environment and life experience? Should promotion focus be cultivated in education? If so, what would be the impact? After all, there are important uses for prevention focus, such as corporate security and compliance. Meanwhile, how can workplaces be organized to bring out the best in both kinds of focus?

Leaders eager to put Zhou’s findings to use right away, meanwhile, might look to the real-world model of Michael DeBakey. Practice viewing new ideas as adventures, seek workplaces that actively push innovation and, above all, cultivate the view that every coworker, high or low, is a potential source of glittering new ideas.

---

This article originally appeared on Rice Business Wisdom.

Jing Zhou is the Mary Gibbs Jones Professor of Management and Psychology in Organizational Behavior at the Jones Graduate School of Business of Rice University. Zhou, J., Wang, X., Song, J., & Wu, J. (2017). "Is it new? Personal and contextual influences on perceptions of novelty and creativity." Journal of Applied Psychology, 102(2): 180-202.

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”